Health for Hungary (H4H) - Longitudinal Collection of Blood Samples and Corresponding Data (NCT07743021) | Clinical Trial Compass
RecruitingNot Applicable
Health for Hungary (H4H) - Longitudinal Collection of Blood Samples and Corresponding Data
Hungary15,000 participantsStarted 2021-07-27
Plain-language summary
The Health for Hungary (H4H) study collects blood samples and corresponding health data to investigate healthy aging and health-to-disease transitions in middle-aged and elderly participants.
Indications Studied:
Apparently healthy, symptom-free participants are enrolled and followed up to study the onset of new-onset diseases with special emphasis on non-communicable diseases (NCDs).
Study Design:
Single-country, multicenter, prospective, longitudinal survey.
Objectives:
The study aims to establish reference ranges of blood parameters using routine clinical blood tests and high-information-content methods, including proteomics, metabolomics and the so-called infrared molecular fingerprinting.
The study also aims to identify novel biomarkers of major non-communicable diseases, including atherosclerotic cardiovascular disease, cancer, diabetes and chronic respiratory disease.
Who can participate
Age range
40 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Signed informed consent form (ICF) of the study.
. Age \> 40 years.
. Willingness to fill in the study questionnaire.
. No clinically relevant symptoms as assessed by the investigator, subjects with existing medical conditions may be eligible given that they are symptom free and that full treatment of the condition is medically confirmed.
. Willingness to participate in future visits.
Exclusion criteria
. Self-reported pregnancy (no test).
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Healthy aging
Timeframe: 10 years
2
Coronary artery disease
Timeframe: 10 years
3
Lung cancer
Timeframe: 10 years
4
Type 2 Diabetes
Timeframe: 10 years
Trial details
NCT IDNCT07743021
SponsorCenter for Molecular Fingerprinting Research Nonprofit LLC
. Indications of clinically relevant medical conditions in self-reported healthy subjects.
. Self-reported symptom-free HIV, HCV and HBV infections. If HIV, HBV or HCV serology test is done and any of them are positive, the subject will be considered a screen failure.
. Any conditions preventing blood-draw.
. Vulnerable subjects.
. Foreseeable lack of compliance.
. Participation in another sample collection project of the same sponsor, in order to avoid double evaluation of the same subject.
. Participation (currently or in the past month) in an early phase clinical trial (phases I and II) involving testing of pharmaceutical products, if the last dose of pharmaceutical product administration was within 30 days of the first sample collection, and / or further pharmaceutical product administration is planned.